Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have been assigned an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $62.8333.

Several equities research analysts recently weighed in on SUPN shares. Wall Street Zen lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Cantor Fitzgerald increased their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 6th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Public Employees Retirement System of Ohio purchased a new position in Supernus Pharmaceuticals in the 2nd quarter valued at approximately $25,000. Rockefeller Capital Management L.P. lifted its position in shares of Supernus Pharmaceuticals by 354.8% during the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after acquiring an additional 660 shares in the last quarter. Torren Management LLC bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth $49,000. EverSource Wealth Advisors LLC bought a new position in shares of Supernus Pharmaceuticals in the second quarter worth $51,000. Finally, Hantz Financial Services Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 73.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 458 shares during the period.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $45.85 on Monday. The stock has a fifty day simple moving average of $46.74 and a two-hundred day simple moving average of $48.83. Supernus Pharmaceuticals has a 1-year low of $42.45 and a 1-year high of $59.68. The firm has a market cap of $2.67 billion, a price-to-earnings ratio of -23.88, a price-to-earnings-growth ratio of 0.85 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The firm had revenue of $219.06 million during the quarter, compared to the consensus estimate of $205.31 million. During the same quarter in the previous year, the firm earned $0.40 earnings per share. The business’s quarterly revenue was up 32.4% compared to the same quarter last year. Analysts forecast that Supernus Pharmaceuticals will post 1.97 EPS for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.